AVEO AVEO Pharmaceuticals Inc

(e) On January 21, 2021, AVEO Pharmaceuticals, Inc. (the “Company”), announced the departure of Karuna Rubin, senior vice president and general counsel, effective immediately. In connection with Ms. Rubin’s departure, on January 25, 2021, the Company entered into an agreement (the “Agreement”) with Ms. Rubin which confirms the terms of her separation. Pursuant to the Agreement, Ms. Rubin will be entitled to receive benefits in connection with her separation that are substantially comparable to the benefits for which she would be eligible in the event of a termination without cause or resignation from employment for good reason, as described in her severance and change in control agreement, dated March 13, 2019, the terms of which were previously disclosed in the Company’s Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities Exchange Commission on March 14, 2019, and are incorporated by reference herein. In addition, pursuant to the Agreement, following the effective date of the Agreement, the vesting of each option to purchase shares of the Company’s common stock granted to Ms. Rubin shall become accelerated with respect to the number of shares of Company common stock that would have vested had Ms. Rubin remained employed with the Company for a period of six months following the effective date of the Agreement. Ms. Rubin will have 180 days from the effective date of the Agreement to exercise any vested options to purchase shares of the Company’s common stock. Further, Ms. Rubin will receive a bonus of $149,839.00, as an annual bonus for the fiscal year 2020, which she would have been eligible for had she remained with the Company. Ms. Rubin also agreed to execute a release of all claims in favor of the Company. If Ms. Rubin revokes such release of claims, she will forfeit the right to receive all transition and separation benefits in accordance with the terms of the Agreement.